Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Industry News

Penumbra Announces First Patient Enrolled In Study Of Mechanical Power Aspiration For Thrombus Removal In Coronary Vessels

October 10, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Industry News

Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

January 22, 2018

News Industry News

Penumbra Introduces POD® Packing Coil for the Embolization of Peripheral Vessels and Aneurysms

January 05, 2016

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Industry News

AngioDynamics Announces First Patient Enrollment in RAPID Outcomes Database

August 06, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Industry News

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

February 24, 2015

News Industry News

Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG

September 02, 2014

News Industry News

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

July 23, 2014

Advertisement

Penumbra Announces First Patient Enrolled In Study Of Mechanical Power Aspiration For Thrombus Removal In Coronary Vessels

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

Penumbra Introduces POD® Packing Coil for the Embolization of Peripheral Vessels and Aneurysms

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

AngioDynamics Announces First Patient Enrollment in RAPID Outcomes Database

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

UK launch for Daiichi's bloodthinner Lixiana

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content